JNJ-70218902) for participants currently receiving the active study treatment in parent studies and deriving benefit from it. Eligible participants in parent study will rollover to this platform study

2 trials

Sponsors

Janssen-Cilag International NV, Yoshinari Nozomi

Conditions

Leukemia, Myeloid, Acute Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-HodgkinNon-Hodgkin lymphoma and chronic lymphocytic leukemia Cancer

Phase 1

A rollover study for continued study treatment and ongoing safety monitoring

RecruitingISRCTN87946208

Janssen-Cilag International NVNon-Hodgkin lymphoma and chronic lymphocytic leukemia Cancer

Start: 2024-12-31Target: 77Updated: 2025-03-31

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Active, not recruitingJPRN-jRCT2041240191

Yoshinari NozomiLeukemia, Myeloid, Acute Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin

Start: 2025-02-19Target: 80Updated: 2026-06-29